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Critical Appraisal of Endometriosis 
Management for Pain and Subfertility 
N. F. Zuberi,J. H. Rizvi  ( Department of Obstetrics and Gynaecology, The Aga Khan University, 
Karachi. ) 
 
Introduction  
Endometriosis can be seen as a continuum that is only considered pathological when a 
certain threshold of severity has been reached.1 Minimal or mild endometriosis is 
increasingly viewed as part of normal physiologic process, whereas the more severe 
forms - ovarian cysts and deeply infiltrating lesions- are considered 'endometriotic 
disease.2 Estimates from asymptomatic fertile subpopulations undergoing tubal ligation 
have varied greatly, from 0.7 to 43% around a mean of 4%.3 However, up to 90% of 
these women were diagnosed with minimal or mild endometriosis.  
 
Understanding the environmental and genetic epidemiology of endometriosis is essential 
for identification of appropriate subjects and effective therapy. Our understanding of 
endometriosis is severely compromised as studies failed to take account of basic 
epidemiological principles in their design. Of 100 studies of environmental risk-factors 
reviewed by Eskenazi and Warner3, only six met the following basic criteria for adequate 
study design:  
 
(i) cohort or case-control design;  
(ii) surgically confirmed cases; 
(iii) clearly described criteria for control selection; and (iv) adjustment for confounding 
factors in the analysis.  
 
There is now good evidence that the assessments patients make about their health differ 
from the proxy reports other health professionals make about their patients' well-being.4 
It is important therefore to evaluate from the patients' perspective the ways in which 
treatments are affecting their health-related quality of life. The areas of well-being and 
functioning that may be important to women, with endometriosis that can lead to a 
diminished quality of life, have been identified as: feelings of control and powerlessness, 
unable to conceive, ineffectiveness of treatments, lack of social support, impaired sexual 
functioning, lack of self image, lack of emotional well-being, pain, relationship with 
children, performance at work place and dissatisfaction with medical professionals.5  
These dimensions have previously been overlooked but are specific to the experiences of 
women with endometriosis and should be taken in account when deciding about modality 
of treatment. In this clinical review we will focus on treatment of pain and infertility 
ascribable to endometriosis as they also influence other areas of well-being and 
functioning which are important to women with endometriosis.  
 
 
Methods  
Our electronic searches targeted all therapeutic modalities among studies on treatment of 
endometriosis. We searched general bibliographic databases: Medline (1966-2001) and 
specialist computer databases: the Cochrane Library6, Bandolier7, Clinical Evidence8, 
Database of Abstracts of Review of Effectiveness (DARE)9 and National Guideline 
Clearinghouse (NGC).10 We also checked reference lists of known reviews and primary 
articles to identify cited articles not captured by electronic searches. 
The selection criteria were systemic reviews and randomized controlled trials (RCTs) in 
treatment of pain and subfertility ascribable to endometriosis, Electronic searches were 
scrutinised and full manuscripts were obtained of all citations that were likely to meet the 
predefined criteria. Final inclusion or exclusion decisions were then made after 
examining these manuscripts. In cases of duplicate publication we selected the most 
recent and complete versions. Due to logistic reasons we restricted our search to English 
language. In presenting this critical appraisal, we adopted the evidence-based approach of 
formulating answerable clinical questions11 for different clinical possibilities. 
 
Pain ascribable to endometriosis  
 
Question 1.  
In women with pain ascribable to endometriosis, does hormonal treatment at diagnosis 
compared with placebo reduce pain? 
 
Assessment of Search  
 
See Table 1 for details. 
 
Outcomes and Intervensions examined  
For relief of pain, 6 months of continuous ovulation suppression was done using Danazol, 
Gestrinone, Depot medroxyprogesterone acetate (DMPA), Dydrogesterone, Oral 
contraceptives or GnRH-analogues 
 
Critically appraised results  
1. Dydrogestrone given at two different doses in the luteal phase, showed no evidence of 
effect. 
2. Combined oral contraceptives (COC) vs GnRH-analogues, no significant difference in 
pain reduction was found. 
1. Danazol (200 mg/day) vs Gestrinone (2.5 mg twice weekly), no significant difference 
in pain reduction was found. 
2. DMPA (150 mg q 3 months) vs COC+Danazol (50 mg/day), DMPA was more 
effective at reducing dysmenorrhoea. 
 
Answer  
All hormonal treatments at diagnosis, except for dydrogesterone, reduce pain ascribable 
to endometriosis compared with placebo, and are equally effective at 6-months 
 
Question 2.  
In women with pain ascribable to endometriosis, does laparoscopic uterine nerve ablation 
(LUNA) compared with laparoscopic treatment without LUNA reduces pain? 
 
Assessment of Search  
 
See Table 1 for details. 
 
Outcomes and Intervensions examined  
 
For relief of pain, LUNA was compared with laparoscopic treatment without LUNA in 
132 women, age range 18-40 years, with endometriosis of stages I-III in two RCTs. 
 
Critically appraised results  
1. No significant difference in pain relief between both groups. 
2. Patient satisfaction was high in both groups (68 v 73%) 
 
Answer  
There is insufficient evidence at present on the effects of LUNA in women with pain 
ascribable to endometriosis.(results awaited of ongoing study). 
 
Question 3.  
In women with pain ascribable to endometriosis, does laparoscopic ablation of 
endometriotic deposits along with laparoscopic uterine nerve ablation (LUNA) compared 
to diagnostic laparoscopy reduce pain? 
 
Assessment of Search  
See Table 1 for details. 
 
Outcomes and Interventions examined  
 
Reduced pain at 6 months after laparoscopic ablation plus LUNA was compared with 
diagnostic laparoscopy in 63 women with mild to moderate endometriosis. 
 
Critically appraised results  
 
1. No RCT evaluating laparoscopic ablation of endometriotic deposits was found. 
2. Median decrease in pain score of 2.85 for ablation was seen versus 0.05 for diagnostic 
laparoscopy, p=0.01 
 
Answer  
Combined treatment with ablation of deposits plus LUNA reduces pain more than 
diagnostic laparoscopy at 6 months. 
 
Question 4.  
In women with pain ascribable to endometriosis, does postoperative hormonal treatment 
compared with placebo significantly reduces pain? 
 
Assessment of Search  
 
See Table 1 for details. 
 
Outcomes and Interventions examined  
 
Reduced pain at 6 months 
 
Critically appraised results  
1. Postoperative danazol (600mg/day) v placebo for 3 months, No significant difference 
in pain relief 6 months after finishing treatment 
2. Danazol 100 mg/day for 6 months v expectant management (after conservative surgery 
followed by monthly injections of decapeptyl for 6 months), danazol significantly 
reduced pain at 12 months and 24 months 
3. Postoperative Danazol (600 mg/day) or Medroxyprogesterone (100 mg/day) for 180 
days v placebo, more reduction in pain at 6 months with danazol 
4. GnRH-analogues 6 months v placebo, significantly reduced pain scores and delayed 
recurrence of pain by more than 12 months with GnRH-analogues.  
 
Answer  
Six-months of postoperative hormonal treatment verses placebo significantly reduces 
pain and delays the recurrence of pain while treatment for 3 months did not seem to be 
effective. 
 
Question 5.  
In women with pain ascribable to endometrioma, does laparoscopic cystectomy 
compared with laparoscopic drainage of ovarian cyst significantly reduces pain? 
 
Assessment of Search  
 
See Table 1 for details. 
 
Outcomes and Interventions examined  
1 RCT evaluating comparison of laparoscopic cystectomy with laparoscopic drainage of 
ovarian cyst was found.  
Reduced recurrence of pain  
Increased pain free interval after operation Critically appraised results  
1. Laparoscopic cystectomy reduced pain at 2 years. 
2. Laparoscopic cystectomy increased the pain free interval after operation (median 
interval 19 months v 9.5 months; p value <0.05)  
 
Answer  
Laparoscopic cystectomy reduces pain more than laparoscopic drainage of 
endometriomas. The recurrence rate of endometriomas after drainage /aspiration was 
high. 
 
Subfertility ascribable to endometriosis  
 
Question 1.  
In women with subfertility ascribable to endometriosis, does hormonal treatment at 
diagnosis compared with placebo improve fertility? 
 
Assessment of Search  
 
See Table 2 for details.  
 
Outcomes and Intervensions examined  
Attempting conception for more than 12 months following 6 months treatment with 
Danazol, Medroxyprogesterone, or Gonadorelin (GnRH) analogues. 
Critically appraised results 
1. Danazol vs Placebo, no significant effect on the likelihood of pregnancy was found. 
2. Medroxyprogesterone vs Placebo, no significant effect on the likelihood of pregnancy 
was found. 
 
Answer  
No evidence that hormonal treatments at diagnosis improve fertility. 
 
Question 2.  
In women with subfertility ascribable to endometriosis, does laparoscopic 
ablation/excision of endometriotic deposits compared with diagnostic laparoscopy 
improve fertility? 
 
Assessment of Search  
 
See Table 2 for details. 
 
Outcomes and Interventions examined  
Relative risk of pregnancy after 36 weeks or pregnancy rates at end of 12 months 
following laparoscopic ablation/excision of mild to moderate endometriotic deposits. 
 
Critically appraised results  
1. In larger trial of 341 women, laparoscopic surgery significantly increased cumulative 
pregnancy rates (follow-up of 36 weeks) 
2. In a smaller more recent trial of 101 women, no significant difference in pregnancy 
rates was found (follow-up of 12 months) 
 
Answer  
Laparoscopic ablation/excision of endometriotic deposits may improve fertility. (results 
awaited of ongoing trials) 
 
Question 3.  
In women with moderate or severe endometriosis, does postoperative hormonal treatment 
compared with placebo improve fertility? 
 
Assessment of Search  
 
See Table II for details. 
 
Outcomes and Interventions examined  
 
Pregnancy rates and time to conception. 
 
Critically appraised results  
1. For all stages of endometriosis no effect of postoperative hormonal therapy was found 
on pregnancy rates and time to conception 
 
Answer  
No evidence of an effect of postoperative hormonal treatment on fertility. 
 
Question 4.  
In women with subfertility ascribable to endometrioma, does laparoscopic cystectomy 
compared with laparoscopic drainage of ovarian cyst significantly improves fertility? 
 
Assessment of Search 
 
See Table 2 for details. 
 
Outcomes and Intervensions examined  
 
Pregnancy rates. 
Critically appraised results  
1. 1 RCT evaluating comparison of laparoscopic cystectomy with laparoscopic drainage 
of ovarian cyst was found. 
2. Laparoscopic cystectomy improved pregnancy rates after operation (67% v 24 %; p 
value <0.05). 
 
Answer  
Laparoscopic cystectomy improves fertility more than laparoscopic drainage of 
endometriomas.  
 
Conclusions  
Surgical resection of endometriosis, previously possible only by means of laparotomy, 
can now be accomplished through laparoscopic techniques. There is a learning curve to 
achieve these skills which can be accomplished. Treatment of adnexal masses by 
operative laparoscopy can be performed safely, with reduced morbidity and patient 
disability, and at a reduced cost.33 Although randomised control trials are lacking, a 
recent critical appraisal showed laparoscopic surgery to be equivalent to laparotomy for 
ovarian endometriosis.34 In a comparison of two surgical series for recurrent 
endometriosis35 rate of recurrence of dyspareunia and need for third surgery was higher 
in laparotomy series. While no significant difference was found between the cumulative 
pregnancy rates at 24 months in the two groups.  
 
Our review of current best available evidence for the management of endometriosis 
strongly suggests an urgent need to modify conventional clinical practices in favour of 
evidence-based practice recommendations. 
 
Best Practice Points  
1. Hormonal treatments (combined oral contraceptives, Danazol or Depot 
medroxyprogesterone acetate) for pain are effective but should be used for six months. 
2. Surgical treatments (ablation of endometriosis and LUNA) are effective treatments for 
pain. 
3. Pre or post hormonal treatments for subfertility are not useful - they do not improve 
pregnancy rates. 
4. The most effective treatment for endometriomas is Cystectomy or ablation of cyst wall 
rather than aspiration or drainage.  
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